Surgical outcome of epicanthus and telecanthus correction by C-U medial canthoplasty with lateral canthoplasty in treatment of Blepharophimosis syndrome.

PURPOSE: To evaluate the surgical outcome of epicanthus and telecanthus correction by C-U medial canthoplasty with lateral canthoplasty in Blepharophimosis Syndrome. PATIENTS AND METHODS: This was a retrospective single arm interventional study including 18 eyes of 9 patients with Blepharophimosis-ptosis-epicanthus inversus syndrome who presented to oculoplastic clinic, ophthalmology department, Qena university hospital in the period of between July 2020 to April 2021. All the patients had BPES with epicanthus and telecanthus. All cases were subjected to by C plasty with medial and lateral canthoplasty for correction of epicanthus and telecanthus correction followed by frontalis suspension surgery to correct the co-existing blepharoptosis. RESULTS: The study included 9 cases of BPES, 6 boys and 3 girls, the mean age was 5.4 ± 1.5 in the study group, all patients had a positive family history for BPES. After surgery, the mean IICD decreased from 38.44 mm preoperatively to 32.8 mm postoperatively, with a mean difference of 6.2 mm (P <  0.001). Likewise, the mean PFL increased from 20.78 mm preoperatively to 26.63 mm postoperatively, with a mean difference of 5.8 mm (P <  0.001). Epicanthus skin fold disappeared in all cases and medical canthus could be seen with well healed difficulty seen scars. CONCLUSION: C-U medial canthoplasty with lateral canthoplasty in Blepharophimosis Syndrome was found to be an effective procedure in the correction of epicanthus and telecanthus.

Synthesis, characterization and antidiabetic effects of vanadyl(II) adenosine monophosphate amino acid mixed-ligand complexes.

Aim: This research paper is aimed at designing a novel insulin alternative for the treatment of diabetes. Materials & methods: Six novel vanadyl(II) compounds, [(AMP-2)(VO+2)(AA n -1)]·NH4 +1, were synthesized from an equimolar ratio of adenosine monophosphate, VOSO4 and amino acids (AA n ). Results: The magnetic moments and electronic spectra revealed the square pyramidal geometrical structure of the complexes. In an in vivo study, the insulin levels, blood glucose levels, lipid profiles and histology of the pancreas and liver of the animals treated with the complexes were similar to those of healthy control animals, unlike the untreated and vanadyl sulfate(II)-treated diabetic ones. Conclusion: The data gathered in the current research illustrated that vanadyl(II)-AMP-amino acid (AA) mixed-ligand complexes can function as antidiabetic agents.

Spectroscopic, structural and magnetic investigations of iron(II) complexes based on 1-isopropyl- and 1-isobutyl-substituted tetrazole ligands.

Two partly new [Fe(intz)6](BF4)2 complexes with n = 3 and 4 (i3tz = 1-isopropyl-1H-tetrazole, i4tz = 1-isobutyl-1H-tetrazole) were synthesized and characterised by X-ray powder diffraction, magnetic susceptibility measurements, vibrational, electronic and 57Fe-Mößbauer spectroscopy as well as DSC. The [Fe(i3tz)6](BF4)2 complex was re-investigated and shows an incomplete spin transition at Tc âˆ¼ 109 K, while the [Fe(i4tz)6](BF4)2 features a complete but rather gradual spin transition with T½ = 223 K. In the lack of suitable crystals of [Fe(intz)6](BF4)2 with n = 3 and 4, we synthesized crystals of [Ni(intz)6](BF4)2 with n = 3 and 4, determined their X-ray crystal structures, and proved them to be homeotypic with the respective Fe-complexes by X-ray powder diffraction. DSC measurements showed an endothermic peak for the [Fe(i3tz)6](BF4)2 around T = 260 K not corresponding to a spin transition and suggesting a structural phase transition at this temperature. A well-developed peak at Tp = 225 K matches the spin-transition temperature T½ = 223 K for [Fe(i4tz)6](BF4)2.